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Abstract
 
The association of invariant (Ii) chain with major histocompatibility complex (MHC) class II
dimers is required for proper antigen presentation to T cells by antigen-presenting cells. Mice
lacking Ii chain have severe abnormalities in class II transport, T cell selection, and B cell mat-
uration. We demonstrate here that H2-M, which is required for efficient class II antigenic
peptide loading, is unexpectedly downregulated in splenocytes and mature dendritic cells
 
(DCs) from Ii
 
2
 
/
 
2
 
 mice. Downregulation reflects an increased rate of degradation in Ii
 
2
 
/
 
2
 
 cells.
Degradation apparently occurs within lysosomes, as it is prevented by cysteine protease inhib-
itors such as E64, but not by the proteasome inhibitor lactacystin. Thus, Ii chain may act as a
lysosomal protease inhibitor in B cells and DCs, with its deletion contributing indirectly to
the loss of H2-M.
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Introduction
 
MHC class II molecules are heterodimeric cell surface gly-
coproteins that bind exogenously derived antigenic peptides
 
and present them to CD4
 
1
 
 T cells (1, 2). Class II 
 
a
 
 and 
 
b
 
chains are translocated into the endoplasmic reticulum
(ER), where they form nonamers with invariant (Ii) chain
(3). Ii chain prevents the binding of immunogenic peptides
due to the presence of a 14–amino acid domain (CLIP) that
occupies the peptide-binding groove of 
 
a
 
/
 
b
 
 dimers (3). Af-
 
ter Ii degradation in the endocytic pathway, the MHC-
encoded molecules HLA-DM (or H2-M in the mouse) and
HLA-DO (H2-O) facilitate the removal of CLIP from 
 
a
 
/
 
b
 
dimers, allowing peptide binding (4–6).
Ii chain has been implicated in functions such as ER ex-
port, endosome targeting, and even B cell maturation (3, 7).
Two alternatively spliced Ii isoforms exist (p31 and p41),
distinguished by a 64-residue domain in the lumenal por-
tion of p41 (8). The isoforms are expressed differently in
various APCs and regulate the presentation of certain anti-
gen epitopes in B cells (9). This difference may reflect pro-
tease inhibition by the amino acid insertion in p41, as it has
been shown to inhibit the lysosomal cysteine protease
cathepsin L both in vitro and in vivo (9, 10). Therefore, Ii
chain may contribute to the modulation of the proteolysis
in the endocytic pathway and thus modulate antigen pro-
cessing indirectly (11, 12). We demonstrate here that Ii
chain deletion leads to the lysosomal degradation of H2-Mb
in APCs, suggesting that Ii chain is required to prevent the
proteolysis of H2-M and perhaps of other proteins. This
feature may help explain how Ii chain expression affects T
cell selection and B cell maturation independently from its
effect on MHC class II traffic (13–15).
 
Materials and Methods
 
Mice and Cell Culture.
 
C57BL/6 (control) and Ii
 
2
 
/
 
2
 
, Ii p31
 
lo
 
(14, 16), class II
 
2
 
/
 
2
 
, and class II/Ii
 
2
 
/
 
2
 
 mice (the gift of P. Mar-
rack, University of Colorado Health Sciences Center, Denver,
CO) were kept in a pathogen-free environment for 7–8 wk be-
fore killing. Splenocytes were obtained as described (7). Bone
marrow–derived dendritic cells (DCs) were cultured as described
(17). After purification, immature DCs were characterized by im-
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munofluorescence and processed in parallel with the LPS-treated
DCs. Epidermal sheets from mouse ears were explanted and fixed
with 3.5% paraformaldehyde (17).
 
RNA Analyses.
 
Poly(A)
 
1
 
 RNA purification and PCR were
performed as described (18). The primers used here to detect
I-A
 
b
 
 
 
a
 
, H2-M
 
a
 
, and H2-M
 
b
 
 are identical to the primers described
previously (19).
 
Pulse–Chase Radiolabeling Experiments.
 
3 
 
3 
 
10
 
7
 
 late DCs were
pulse labeled with 7.5 mCi/ml of [
 
35
 
S]methionine Translabel
(ICN) and chased as described (17). 
 
a
 
/
 
b
 
2
 
 H2-M was immuno-
precipitated with the rat mAb 2C3A (a gift of L. Karlsson, R.W.
Johnson Research Institute, San Diego, CA) and protein A–Seph-
arose.
 
 
 
Quantification was performed using a PhosphorImager
 
®
 
(Molecular Dynamics).
 
Antibodies and Immunofluorescence.
 
Murine I-A was detected
using Rivoli, a rabbit polyclonal antibody directed against the
conserved class II I-A 
 
b
 
 chain cytoplasmic tail (17); H2-Mb was
detected by immunofluorescence and immunoblots with the rab-
bit polyclonal antibodies anti–H2-Mb Ulm (17), K553 (19; a gift
of L. Karlsson) and anti–H2-Mb cytoplasmic tail (a gift of S.
Amigorena, Institut Curie, Paris, France). Rabbit polyclonal anti–
human cathepsin B was from Calbiochem. Murine lgp-B/lamp-2
and Ii chain were detected using the rat mAbs GL2A7 (17) and
In1 (20). For immunofluorescence, cells were fixed in 3.5%
paraformaldehyde (in PBS) and permeabilized as described (17).
All secondary antibodies were purchased from Jackson Immu-
noResearch Laboratories.
 
Protease Inhibitors.
 
The cathepsin S–specific inhibitor LHVS
(a gift of Hidde Ploegh, Harvard Medical School, Boston, MA)
was added to the culture medium of late DCs (preincubated with
LPS for 18 h) at the concentration of 2 nM and 1 
 
m
 
M. E64 was
obtained from Sigma Chemical Co. and used at 20 
 
m
 
M. The
cathepsin B–specific inhibitor CA074me used at 5 
 
m
 
M was ob-
tained from Bachem.
 
Results and Discussion
 
Ii chain is responsible for the correct folding and trans-
port of MHC class II in APCs. However, discrepancies be-
tween class II transport and T cell selection in Ii
 
2
 
/
 
2
 
 mice
suggested that Ii chain deletion may epistatically affect an-
other critical component of antigen processing, such as H2-M.
To investigate a possible relationship between Ii chain de-
letion and H2-M expression, we isolated splenocytes from
wild-type and Ii
 
2
 
/
 
2
 
 mice and probed for H2-M by West-
ern blot. As shown in Fig. 1 A, greatly decreased steady-
state levels of H2-Mb (
 
,
 
5% of control) were detected in
Ii
 
2
 
/
 
2
 
 splenocytes, whereas similar levels of cathepsin B were
detected.
We next asked if the decrease in H2-M might somehow
reflect the ER accumulation of misfolded class II molecules
that occurs in the absence of Ii chain (16). Misfolded class
II might interact with H2-M resulting in ER retention and
degradation. However, H2-M levels were reduced in sple-
nocytes derived from Ii
 
2
 
/
 
2
 
 and class II
 
2
 
/
 
2
 
 double deficient
mice (Fig. 1 B). Thus, Ii chain affected H2-M expression
independently of its interaction with MHC class II.
To determine if H2-M disappearance correlated with the
amount of Ii chain expressed, we quantified H2-Mb pro-
tein in splenocytes from Ii
 
2
 
/
 
2
 
 mouse reconstituted with the
p31 isoform of Ii chain at very low level of expression
(p31
 
lo
 
 [14]). Surprisingly, even small amounts of p31 (1% of
wild-type) disproportionately protected against H2-M dis-
appearance, allowing its accumulation at much higher lev-
els (20% of control; Fig. 1 B), despite the fact that Ii expres-
sion in p31
 
lo
 
 splenocytes was insufficient to restore proper
class II transport (14).
mRNA levels of MHC class II and H2-M molecules
were determined by reverse transcription (RT)-PCR (Fig.
1 C). No differences in the levels of I-A
 
b
 
, H2-M
 
a
 
, or H2-
M
 
b
 
 mRNA could be detected in mice lacking Ii chain
(Ii
 
2
 
/
 
2
 
), mice expressing low levels of the p31 (p31
 
lo
 
) chain
(14), or control C57BL/6 mice (Fig. 1 C). Therefore, the
absence of Ii chain had no effect on the transcription of
MHC class II and H2-M, suggesting that H2-Mb down-
regulation occurred posttranslationally.
DCs activate Ii chain degradation during maturation
(20), suggesting that the absence of Ii chain might some-
how render H2-M more susceptible to degradation. H2-M
distribution was examined in immature and mature (LPS-
Figure 1. H2-M is downregulated in Ii2/2 mouse splenocytes. (A) Sple-
nocytes were isolated from control (C57BL/6, Con) or Ii2/2 mice. After
separation by SDS-PAGE, samples were immunoblotted and H2-Mb was
detected using the rabbit polyclonal antibody K553. A severe depletion of
H2-M (95%) can be observed in the Ii-deleted mice. (B) Splenocyte ex-
tracts from control (C57BL/6), Ii2/2, Ii/MHC class II (CII)2/2, or p31lo
mice were immunoblotted for H2-Mb with an anticytoplasmic tail or
K553. H2-Mb1 (right) appears as a doublet due its single N-glycosylation
detected by the cytoplasmic-tail antibody used here instead of K553,
which does not detect this form (left). In Ii chain–deleted mice and double
knockout mice, the H2-M level was strongly reduced compared with the
control mice (left). However, in p31lo mice (right), H2-M levels were
found to be intermediate between control and knockout mice, suggesting
a direct correlation between Ii chain levels and H2-M disappearance. (C)
To determine if H2-M downregulation was occurring at the transcrip-
tional level, RT-PCR was performed on control, Ii2/2, p31lo, and H2-
Ma2/2 mice. All levels of transcription for I-Ab a, H2-Ma, and H2-Mb
are found to be identical except in the control mice lacking H2-Ma. 
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treated) bone marrow–derived DCs from control and Ii
 
2
 
/
 
2
 
mice. DCs were stained for H2-M and the lysosomal
marker protein lgp-B/lamp-2 and observed by confocal
microscopy. In immature DCs, still in clusters (Fig. 2 A),
the staining intensity of H2-Mb and its colocalization with
lgp-B/lamp-2 were similar in cells obtained from control
or Ii
 
2
 
/
 
2
 
 mice. This was confirmed by staining immature
Langerhans cells
 
 
 
in situ, in which similar amounts of H2-M
were detected in Ii
 
2
 
/
 
2
 
 and control epidermis (Fig. 2 B).
Thus, in immature DCs, the absence of Ii chain did not af-
fect delivery of H2-M to the lysosomes (21) or lead to its
downregulation.
However, in mature DCs H2-M was barely detectable
in cells from Ii
 
2
 
/
 
2
 
 mice (Fig. 3). The lgp-B/lamp-2 stain-
ing in these cells was indistinguishable from controls and
exhibited a distinct perinuclear pattern characteristic of ma-
ture DCs (17). As expected from the Western blot experi-
ments, H2-M was not noticeably downregulated in class
II
 
2
 
/
 
2
 
 DCs (Fig. 3).
To evaluate the half-life of H2-Mb, a pulse–chase exper-
iment was performed. Control and Ii
 
2
 
/
 
2
 
 mature DCs were
radioactively labeled for 30 min and chased for various
lengths of time. H2-M was then immunoprecipitated and
quantified by PhosphorImager
 
®
 
. Since the H2-Mb band
was most readily quantifiable, we determined its half-life at
42 h in controls but only 10 h in the Ii
 
2
 
/
 
2
 
 cells (Fig. 4 B).
The rapid degradation of H2-Mb in the Ii
 
2
 
/
 
2
 
 cells could be
at least partially slowed by adding 1 
 
m
 
M LHVS, a cysteine
Figure 2. H2-M is not affected in Ii2/2 immature
DCs. (A)  Immunofluorescence microscopy of bone
marrow–derived purified clusters of immature DCs
stained for H2-Mb (green) and lamp-2 (red). Control
cells (left) and Ii2/2 cells (right) do not display any dif-
ference for H2-M levels. (B) Confocal immunofluores-
cence microscopy of immature Langerhans cells from
control (left) and Ii2/2 mice (right) stained for H2-M
(red). No difference in H2-M staining intensity could
be detected between these immature Langerhans cells.
Figure 3. H2-M is downregulated in Ii2/2 but not class II2/2 mature
DCs. Mature LPS-treated control DCs (left) were stained for class II (top,
green) and lgp-B/lamp-2 (bottom, red) to demonstrate the maturity of
these cells. Control and deleted mature DCs were stained for H2-Mb
(top, green) and lgp-B/lamp-2 (bottom, red). In mature DCs, lysosomes
converge in the cell center and appear as a unique concentrated H2-M/
lamp-2–positive organelle. H2-M is severely downregulated in Ii2/2
DCs compared with the control or MHC class II (CII)2/2 cells. Lgp-B/
lamp-2 levels (right, red) are found to be unchanged in all of the mice
strains. H2-Mb downregulation is linked to the absence of Ii and to the
maturation of DCs but not to the absence of MHC class II. Some con-
taminating granulocytes are found to be negative for H2-M in control
cells and class II2/2. Bars, 100 mM.1060 Invariant Chain Controls H2-M Proteolysis
protease inhibitor, during the chase period (Fig. 4 B).
However, the effect was only evident at longer time
points, possibly reflecting the time required for the LHVS
to reach inhibitory concentrations within endocytic or-
ganelles. Thus, the disappearance of H2-M upon matura-
tion of Ii2/2 DCs appears to reflect H2-M degradation by
lysosomal cysteine proteases. No differences were ob-
served in acquisition of Endo H resistance, confirming that
Ii chain was not required for transport through the Golgi
complex (19, 21).
As previously observed in B cells (22), in DCs H2-M
could be precipitated with Ii chain after a 30-min pulse,
reflecting the presumptive interaction of these molecules
in the ER (Fig. 4 C). Although both Ii chain splice forms
were coimmunoprecipitated, approximately fivefold more
p41 than p31 was detected, suggesting a higher affinity of
p41 for H2-M. This preference is even far greater, as DCs
express about three times more p31 than p41 (Fig. 4 D).
To further demonstrate the involvement of cysteine
proteases in H2-Mb downregulation, early and late DCs
from control and Ii2/2 mice were incubated with cysteine
protease inhibitors and analyzed by immunoblot (Fig. 5).
Although H2-M was slightly (20%) reduced in early Ii2/2
DCs, a striking decrease was observed in the LPS-treated
mature cells where H2-M was found at only 5% of the
amount in controls. When the mature Ii2/2 DCs were also
treated with the inhibitor E64 (20 mM) or LHVS (1 mM)
(11), H2-M levels were partially rescued to z50% of con-
trol (Fig. 5, A and B). This protective effect was not ob-
served at 2 nM LHVS where only cathepsin S was inhib-
ited (20), suggesting that other cysteine proteases were
responsible for H2-Mb degradation. When 5 mM of the
cathepsin B inhibitor CA074me (9) was used, a slight res-
cue of H2-Mb was observed, suggesting that cathepsin B
might play a role (Fig. 5 C).
To rule out the possible degradation of H2-M in the cy-
tosol, as occurs for misfolded proteins in the ER, mature
Ii2/2 DCs were incubated with lactacystin. Lactacystin is a
proteasome inhibitor known to prevent degradation of free
ER MHC class I (23) and MHC class II (24). 50 mM of lac-
Figure 4. Quantitation of H2-M half-life. (A) Immunoprecipitation of
S35-pulsed and chased H2-M with the mAb 2C3A was performed. H2-
Mb was found to be degraded almost completely after 24 h in Ii2/2 DCs
in contrast to the control (C) DCs. (B) Quantitation of H2-Mb immuno-
precipitated with 2C3A (n 5 2) from control (Con) or Ii2/2 late DCs
treated or not with LHVS (1 mM) during the chase. A clear difference can
be observed after 24 h of chase between the control and Ii2/2 DCs. Inter-
estingly, LHVS treatment during the chase prevents H2-Mb degradation,
suggesting a cysteine protease involvement. (C and D) In control DCs, the
p41 alternatively spliced form of Ii chain is preferentially coimmunopre-
cipitated with H2-M (2C3A) after 30 min of radioactive labeling, whereas
p31 is the main Ii chain isoform immunoprecipitated using the IN1 mAb.
Figure 5. Cysteine proteases inhibition prevents H2-M degradation in
mature DCs. (A) Early and late (LPS-treated) DCs from control (con) or
Ii2/2 mice were purified and treated with protease inhibitor before immu-
noblot for H2-Mb and cathepsin B. H2-Mb was mildly downregulated in
Ii2/2 early DCs and virtually absent from Ii2/2 late DCs. Incubation of
these cells with the cysteine protease inhibitor E64 for 24 h allowed for an
efficient recovery of H2-M. Little variation in cathepsin B expression was
observed between control and Ii-deleted cells (bottom) or during matura-
tion. This observation confirms that H2-M is actively degraded by cys-
teine proteases in the endocytic pathway of late DCs. (B) LHVS at 1 mM
but not at 2 nM (not shown) had the same effect as E64, suggesting that
lysosomal cysteine proteases but not cathepsin S are degrading H2-M. (C)
Ii2/2 DCs were treated for 18 h with 5 mM CA074me, resulting in partial
H2-M rescue. The specificity of CA074 for cathepsin B suggests a role of
this protease in H2-M degradation. (D) Ii2/2 DCs were treated for 18 h
with 50 mM lactacystin, with no effect on H2-M disappearance. MHC
class II (I-Ab) molecules were detected to demonstrate accumulation of
class II aggregates (Aggr) in the lactacystin (Lacta)-treated cells.1061 Pierre et al. Brief Definitive Report
tacystin somewhat enhanced the accumulation of aggre-
gated MHC class II but had no effect on H2-M disappear-
ance in mature Ii2/2 DCs (Fig. 5 D).
The regulation of the degradation of H2-M, through the
inhibition of lysosomal cathepsins, suggests that Ii chain
may function as a protease inhibitor that may help to pro-
tect H2-M and possibly other proteins against proteolysis in
DC lysosomes. This role for Ii chain has been previously
suggested on the basis of two observations. First, a potent
inhibitory effect on cathepsin L is mediated by the 64–
amino acid segment encoded by the alternatively spliced
exon of p41 (9, 10). Second, Ii chain shares significant
amino acid sequence homology (40–45%) with various
cysteine protease inhibitors, the cystatins (25).
Cathepsin L is present at minimal levels in DCs, and its
activation by the absence of Ii or by DC maturation was
not detected (not shown). However, p41 seems to be asso-
ciated preferentially with H-2M, and its protease inhibitory
activity could be relevant for the protection of the dimer.
However, in mice expressing a low level of p31 (p31lo)
H2-M degradation was at least partially reduced. Thus, the
inhibitory effect of Ii chain on degradation is not solely de-
pendent on p41 and is consistent with the fact that p31
bears significant sequence homology to the cystatin super-
family (25). Interestingly, transfection of Ii p31 in fibro-
blasts resulted in the formation of enlarged endosomes and
a delay in transport from endosomes to lysosomes (26). A
similar phenomenon has also been observed in cells treated
with the protease inhibitor E64 or leupeptin, further sup-
porting a protease inhibitory function for Ii chain.
H2-M degradation is dramatically increased with DC
maturation in Ii2/2 mice. We demonstrated recently that
members of family 2 cystatins control the proteolytic en-
docytic environment of immature DCs (20). In immature
Ii2/2 DCs, the lack of Ii chain might be compensated by
antiprotease effects of cystatins, which normally control ly-
sosomal cathepsins in these cells. Upon activation by LPS,
downregulation of cystatins combined with the absence of
Ii chain would render H2-M more susceptible to degrada-
tion. However, in splenocytes the degradation of H2-M
occurs even without LPS activation. Thus, B cells may not
exhibit the type of developmental regulation of protease
activity seen in DCs, or B cells may express a different
complement of proteases to which H2-M is more suscep-
tible.
Ii chain has been implicated in modulating B cell matu-
ration (7, 15) as well as T cell selection (13–15). Surpris-
ingly, significant amounts of peptide-loaded MHC class II
have been detected at the surface of Ii2/2 APCs, especially
DCs expressing the I-Ad and I-Ak haplotypes (13, 15).
These observations suggest that in some strains of Ii2/2
mice, impaired T cell selection is not the direct conse-
quence of an abnormal transport of MHC class II mole-
cules. Our results suggest that H2-M function and there-
fore the peptide repertoire presented may be altered in such
mice. As a consequence, H2-M degradation could contrib-
ute to the observed decrease in CD41 T cells in the thymus
of all Ii chain–deficient strains and the milder phenotype
for maturation of CD41 T cells in the periphery of the Ii2/2
Balb/c (I-Ad) mice (15).
The precise contribution of H2-M disappearance to the
phenotypes observed in Ii2/2 APCs is difficult to establish
because the dependency of MHC class II on both Ii and
H2-M varies greatly according to the haplotype (27). The
fact that mice lacking both Ii and H2-M exhibit a nearly
complete inhibition of CD41 T cell selection supports the
idea that Ii and H2-M deletions are synergistic (28). The
partial rescue of H2-M by low level Ii chain would still ex-
plain why reconstituted mice (p31lo) have normal CD41 T
cell positive selection despite the fact that MHC class II
traffic is still strongly inhibited (14, 15). In any event, the
fact that Ii chain deletion can indirectly cause H2-M
downregulation will indicate that results obtained with Ii2/2
mice should be carefully controlled for the possible contri-
bution of H2-M dysfunction.
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